NEUROCRINE BIOSCIENCES Trademark

Trademark Overview

On Monday, August 16, 2021, a trademark application was filed for NEUROCRINE BIOSCIENCES with the United States Patent and Trademark Office. The USPTO has given the NEUROCRINE BIOSCIENCES trademark a serial number of 90981212. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Wednesday, September 25, 2024. This trademark is owned by Neurocrine Biosciences, Inc.. The NEUROCRINE BIOSCIENCES trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for treatment of Huntington's Disease, chorea associated with Huntington's Disease
neurocrine biosciences

General Information

Serial Number90981212
Word MarkNEUROCRINE BIOSCIENCES
Filing DateMonday, August 16, 2021
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateWednesday, September 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 13, 2022

Trademark Statements

Description of MarkThe mark consists of a stylized circular spiral design with "NEUROCRINE" above "BIOSCIENCES" in block lettering to the right.
Goods and ServicesPharmaceutical preparations for human use for treatment of Huntington's Disease, chorea associated with Huntington's Disease
Indication of Colors claimedColor is not claimed as a feature of the mark.
NOT AVAILABLE"BIOSCIENCES"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 5, 2021
Primary Code005
First Use Anywhere DateThursday, February 1, 2024
First Use In Commerce DateThursday, February 1, 2024

Trademark Owner History

Party NameNeurocrine Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130
Party NameNeurocrine Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events

Event DateEvent Description
Tuesday, October 5, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 19, 2021NEW APPLICATION ENTERED
Wednesday, October 6, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, May 5, 2022COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Thursday, May 5, 2022EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Thursday, May 5, 2022NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Thursday, May 5, 2022EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Friday, November 4, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, November 5, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, November 5, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 3, 2022ASSIGNED TO EXAMINER
Friday, November 4, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, November 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 13, 2022PUBLISHED FOR OPPOSITION
Tuesday, February 7, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, July 20, 2023SOU EXTENSION 1 FILED
Thursday, July 20, 2023SOU TEAS EXTENSION RECEIVED
Thursday, July 20, 2023DIVISIONAL REQUEST RECEIVED
Thursday, July 20, 2023TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, August 9, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 16, 2023DIVISIONAL PROCESSING COMPLETE
Wednesday, August 16, 2023SOU EXTENSION 1 GRANTED
Thursday, August 17, 2023CORRECTED NOA E-MAILED
Thursday, August 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 17, 2024SOU EXTENSION 2 FILED
Wednesday, January 17, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 2, 2024DIVISIONAL REQUEST RECEIVED
Friday, August 2, 2024TEAS STATEMENT OF USE RECEIVED
Friday, August 2, 2024TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, September 25, 2024STATEMENT OF USE PROCESSING COMPLETE
Tuesday, December 13, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, January 17, 2024SOU EXTENSION 2 GRANTED
Friday, August 2, 2024USE AMENDMENT FILED
Wednesday, September 25, 2024DIVISIONAL PROCESSING COMPLETE

Related Keywords

biosciences neurocrine huntington disease associated chorea treatment preparations human pharmaceutical